Status:
RECRUITING
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
Lead Sponsor:
Sun Yat-sen University
Conditions:
Nasopharyngeal Carcinoma (NPC)
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The goal of this clinical trial is to determine the maximum tolerated dose and the recommended phase II dose for nab-paclitaxel when administered concurrently with radiotherapy in nasopharyngeal carci...
Eligibility Criteria
Inclusion
- Pathologically confirmed nasopharyngeal carcinoma
- III-IVa (AJCC8th)
- age 18-70
- PS score 0-1
- normal functions to tolerate chemotherapy and radiotherapy
Exclusion
- The presence of other malignant neoplasms within the preceding five years, with the exception of carcinoma in situ, adequately treated non-melanoma skin cancer and papillary thyroid cancer, is permitted.
- Symptomatic heart failure, unstable angina, myocardial infarction, active infections requiring systemic therapy, psychiatric disorders, or family and social factors
Key Trial Info
Start Date :
August 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06611150
Start Date
August 2 2024
End Date
August 1 2027
Last Update
September 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060